Free Newsletter
Novartis inks pact to enter Japanese vax market
Novartis has struck a deal with Takeda that will allow the Swiss pharma giant entry into the world's third largest vaccine market.
Takeda has agreed to pay Novartis a little more than a million dollars upfront along with milestones and royalties for Vaxem-Hib, a vaccine for the Haemophilus influenza Type B (Hib). Takeda takes on responsibility for clinical trials in Japan and will file the NDA for the vaccine, which will be sold under the Novartis name.
Japan's vaccine market is valued at $640 million and is widely expected to grow more.
- read the report from Reuters
Related Articles:
Novartis pays $20M up front for vax program
Xoma, Novartis restructure vaccine agreement
Novartis plans trials for growing vaccines pipeline
Novartis eyes vaccines with Protez purchase
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: